熱門資訊> 正文
在达拉斯医疗中心启动TULSA程序后，深刻医疗崛起
2025-09-24 00:58
- Shares of Profound Medical (NASDAQ:PROF) traded higher after the company announced that Dallas Medical Center is launching the TULSA procedure, a minimally invasive procedure to treat prostate diseases backed by the company’s TULSA-PRO technology.
- The Canadian MedTech said that Texas Prostate, a Dallas-based prostate treatment center, has partnered with Dallas Medical Center to conduct TULSA procedures for males with prostate cancer and benign prostatic hyperplasia.
- In January, the U.S. Centers for Medicare and Medicaid Services granted Medicare coverage for TULSA procedures performed at three sites of service, including hospital outpatient settings.
- According to Profound (NASDAQ:PROF), the collaboration under which Texas Prostate will exclusively perform TULSA procedures at Dallas Medical's MRI suite will significantly broaden Medicare patient access to the treatment.
More on Profound Medical Corp.
- Profound Medical: Smoke Is Everywhere, Initiate At Sell
- Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
- Profound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidence
- Historical earnings data for Profound Medical Corp.
- Financial information for Profound Medical Corp.
推薦文章
美股機會日報 | 凌晨00:35！鮑威爾將發表重要講話；阿里Qwen團隊今晚將發佈6個「新東西」
華盛早報 | 美聯儲理事米蘭「首秀」，呼籲激進降息；英偉達漲近4%市值突破4.5萬億美元
美股機會日報 | 華爾街樂觀押注：利率降幅將遠超美聯儲預測！以太坊跳水重挫超5%，加密貨幣概念股BitMine盤前一度跌近10%
一圖看懂 | 兩隻易方達ETF開啟認購！入場門檻為1500港元
新股申購 | 博泰車聯今起招股！一手入場費2065.23港元
美股「新寵」驟變：「昔日冷門」硬盤與內存站上AI風口 老牌存儲廠商業績股價齊飛
美聯儲政策路徑不確定性仍存 中期美債備受交易員青睞
特朗普的H-1B簽證10萬美元新規引發科技公司混亂
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
